LACTATED RINGER'S AND 5% DEXTROSE INJECTION, USP 600 MG / 100 ML
SODIUM CHLORIDE : 600 MG / 100 ML CALCIUM CHLORIDE : 20 MG / 100 ML SODIUM LACTATE : 310 MG / 100 ML POTASSIUM CHLORIDE : 30 MG / 100 ML DEXTROSE : 5 G / 100 ML · DIN 00061131 · BAXTER CORPORATION
Health Canada status: MARKETED
What is LACTATED RINGER'S AND 5% DEXTROSE INJECTION, USP?
LACTATED RINGER'S AND 5% DEXTROSE INJECTION, USP 600 MG / 100 ML contains SODIUM CHLORIDE : 600 MG / 100 ML CALCIUM CHLORIDE : 20 MG / 100 ML SODIUM LACTATE : 310 MG / 100 ML POTASSIUM CHLORIDE : 30 MG / 100 ML DEXTROSE : 5 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00061131, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Dec-1973. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LACTATED RINGER'S AND 5% DEXTROSE INJECTION, USP used for?
Indicated as a source of water, electrolytes and calories or as an alkalinizing agent.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00061131 |
|---|---|
| Brand name | LACTATED RINGER'S AND 5% DEXTROSE INJECTION, USP |
| Generic / active ingredient | SODIUM CHLORIDE : 600 MG / 100 ML CALCIUM CHLORIDE : 20 MG / 100 ML SODIUM LACTATE : 310 MG / 100 ML POTASSIUM CHLORIDE : 30 MG / 100 ML DEXTROSE : 5 G / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 600 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BB02 ELECTROLYTES WITH CARBOHYDRATES |
| AHFS class | 40:20.00 ; 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1973 |
| Original market date | 1973-12-31 00:00:00 |
How is it administered?
Intravenous administration. Dosage, rate, and duration individualized based on age, weight, clinical condition, and laboratory response. Do not exceed glucose utilization capacity.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 25°C.
How is it supplied?
VIAFLEX plastic containers in 500 mL size.
Contraindications
Hypersensitivity to ingredients; concomitant ceftriaxone in newborns (≤28 days); simultaneous ceftriaxone via same line in any age; corn allergy; hyperglycemia (>10 mmol/L).
Warnings and precautions
Risk of aluminum toxicity in renal impairment/neonates; fluid/solute overload; hyponatremic encephalopathy; air embolism risk; not for lactic acidosis treatment.
What can be used instead?
Other Canadian products sharing ATC code B05BB02 ELECTROLYTES WITH CARBOHYDRATES. 17 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| (20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | 3.3 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438014 |
| (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00786292 |
| (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438049 |
| (20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00437999 |
| (40 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | 300 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438030 |
| (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438022 |
| (40MMOL/L)POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00438006 |
| 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931598 |
| 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01927531 |
| 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | 50 MG | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01924435 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for LACTATED RINGER'S AND 5% DEXTROSE INJECTION, USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.